Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Modulation of pathogenic T cells in EAE

Award Number: R21AI176366
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 11/13/2023
PERIOD OF PERFORMANCE END DATE: 10/31/2025

Group Awards By:

View Award Description

Modulation of pathogenic T cells in EAE - Project Summary Multiple sclerosis (MS) is a disease characterized by inflammation, demyelination, and neurodegeneration of the central nervous system (CNS). Human genetic studies and adoptive transfer experiments in experimental autoimmune encephalomyelitis (EAE), an animal model of MS point to CD4+ T helper cells as important actors in the development and progression of CNS specific autoimmunity. IL-2 is a cytokine critical for maintaining T cell homeostasis, growth, and proliferation. IL-2 is predominantly produced by activated CD4+ T cells in lymphoid organs. However, this production is lost in most cells and only sustained in a unique fraction of CD4+ T cells. We have developed a novel tool which allow us to track, eliminate and study IL-2+ T cells during the development and progression of EAE. Here, we will determine the identity, characteristics and means to modulate IL-2+ T cells in the context of EAE development and progression and establish whether STAT1 limits IL-2+ T cells and their pathogenic functions. The completion of these studies will provide new insights on the function of IL-2+ cells during prolonged disease progression, establish whether the enhance STAT1 signaling can limit the pathogenic function of these cells, and identify markers of pathogenic IL-2+ T cells and pathways that can be further studied and targeted to limit the activity of these cells in the context of CNS autoimmunity.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $0 )
2026	2025	BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON	1201 9TH AVE	SEATTLE	WA	98101	KING	USA	Allergy and Infectious Diseases Research	000	2	3/4/2026	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2025 ( Subtotal = $210,126 )
2025	2025	BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON	1201 9TH AVE	SEATTLE	WA	98101	KING	USA	Allergy and Infectious Diseases Research	000	2	10/31/2024	NON-COMPETING CONTINUATION	$210,126
														Subtotal = $210,126

Issue Date FY: 2024 ( Subtotal = $259,950 )
2024	2024	BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON	1201 9TH AVE	SEATTLE	WA	98101	KING	USA	Allergy and Infectious Diseases Research	001	1	9/11/2024	NEW	$25,995
2024	2024	BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON	1201 9TH AVE	SEATTLE	WA	98101	KING	USA	Allergy and Infectious Diseases Research	000	1	11/13/2023	NEW	$233,955
														Subtotal = $259,950

Grand Total All Awards = $470,076

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Modulation of pathogenic T cells in EAE

Award Number: R21AI176366

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 11/13/2023

PERIOD OF PERFORMANCE END DATE: 10/31/2025

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer